Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.47 |
| ▸ | HTR2B | P41595 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640909 | 0.83 | SLC6A4 (0.48) | HTR2CHTR2BSLC6A4HTR1ASLC6A2 | |
| SCHEMBL641983 | 0.78 | GAA (0.66) | CXCR2 | |
| SCHEMBL3043147 | 0.78 | POLB (0.49) | HTR2CHTR2BHTR1AIKBKB | |
| Hydrochloric Acid SCHEMBL3040514 | 0.77 | HTR6 (0.49) | HTR2CHTR2BHTR1AIKBKB | |
| SCHEMBL14639871 | 0.76 | PKM (0.39) | SLC6A4HTR2A | |
| SCHEMBL643978 | 0.76 | MAPT (0.48) | CXCR2 | |
| SCHEMBL1673520 | 0.76 | HTR2C (0.54) | HTR2CSLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL4701461 | 0.75 | SLC6A2 (0.77) | HTR2CSLC6A4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL5071388 | 0.75 | DRD2 (0.41) | SLC6A4HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL15819292 | 0.75 | HTR2C (0.55) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | HTR2C 261/4885HTR2B 332/4885SLC6A4 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.